Syncom Formulation (India) (NSE:SYNCOMF) 3-Year Book Growth Rate : 13.40% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Syncom Formulation (India) 3-Year Book Growth Rate?

Syncom Formulation (India)'s Book Value per Share for the quarter that ended in Dec. 2023 was ₹0.00.

During the past 12 months, Syncom Formulation (India)'s average Book Value per Share Growth Rate was 11.70% per year. During the past 3 years, the average Book Value per Share Growth Rate was 13.40% per year. During the past 5 years, the average Book Value per Share Growth Rate was 13.00% per year. During the past 10 years, the average Book Value per Share Growth Rate was 9.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Syncom Formulation (India) was 15.00% per year. The lowest was -17.20% per year. And the median was 6.60% per year.

Competitive Comparison of Syncom Formulation (India)'s 3-Year Book Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Syncom Formulation (India)'s 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Syncom Formulation (India)'s 3-Year Book Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Syncom Formulation (India)'s 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Syncom Formulation (India)'s 3-Year Book Growth Rate falls into.

Syncom Formulation (India) 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Syncom Formulation (India) (NSE:SYNCOMF) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Syncom Formulation (India) 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Syncom Formulation (India)'s 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Syncom Formulation (India) (NSE:SYNCOMF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syncom Formulation (India) Ltd (NSE:SYNCOMF) » Definitions » 3-Year Book Growth Rate

Traded in Other Exchanges

524470:India

Address

207, Saket Nagar, Near Saket Club, Indore, MP, IND, 452018

Website

https://www.sfil.in

Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.

Syncom Formulation (India) (NSE:SYNCOMF) Headlines

No Headlines